These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 15027132

  • 1. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: gamma-linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182,780 (Faslodex) efficacy in human breast cancer cells.
    Menendez JA, Colomer R, Lupu R.
    Int J Cancer; 2004 May 10; 109(6):949-54. PubMed ID: 15027132
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients.
    Santen R, Jeng MH, Wang JP, Song R, Masamura S, McPherson R, Santner S, Yue W, Shim WS.
    J Steroid Biochem Mol Biol; 2001 Dec 10; 79(1-5):115-25. PubMed ID: 11850215
    [Abstract] [Full Text] [Related]

  • 4. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression.
    Menendez JA, Ropero S, Lupu R, Colomer R.
    Oncol Rep; 2004 Jun 10; 11(6):1241-52. PubMed ID: 15138562
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ, Jelovac D, Thiantanawat A, Brodie AM.
    Clin Cancer Res; 2002 Jul 10; 8(7):2378-88. PubMed ID: 12114443
    [Abstract] [Full Text] [Related]

  • 9. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK, Castiglione-Gertsch M.
    Minerva Ginecol; 2009 Dec 10; 61(6):517-39. PubMed ID: 19942839
    [Abstract] [Full Text] [Related]

  • 10. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
    Kim K, Thu N, Saville B, Safe S.
    Mol Endocrinol; 2003 May 10; 17(5):804-17. PubMed ID: 12576490
    [Abstract] [Full Text] [Related]

  • 11. Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
    Raina V.
    Nat Clin Pract Oncol; 2004 Nov 10; 1(1):20-1. PubMed ID: 16264793
    [No Abstract] [Full Text] [Related]

  • 12. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
    Bianco NR, Perry G, Smith MA, Templeton DJ, Montano MM.
    Mol Endocrinol; 2003 Jul 10; 17(7):1344-55. PubMed ID: 12714703
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
    Van Poznak CH, Hayes DF.
    J Natl Cancer Inst; 2006 Sep 20; 98(18):1261-3. PubMed ID: 16985239
    [No Abstract] [Full Text] [Related]

  • 15. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo.
    Leveque J, Foucher F, Havouis R, Desury D, Grall JY, Moulinoux JP.
    Anticancer Res; 2000 Sep 20; 20(1A):97-101. PubMed ID: 10769640
    [Abstract] [Full Text] [Related]

  • 16. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V, Gougelet A, Maillard S, Renoir JM.
    Mol Endocrinol; 2003 Oct 20; 17(10):2013-27. PubMed ID: 12855746
    [Abstract] [Full Text] [Related]

  • 17. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
    Bindels EM, Lallemand F, Balkenende A, Verwoerd D, Michalides R.
    Oncogene; 2002 Nov 21; 21(53):8158-65. PubMed ID: 12444551
    [Abstract] [Full Text] [Related]

  • 18. Influence of n-3 fatty acids on the growth of human breast cancer cells in vitro: relationship to peroxides and vitamin-E.
    Chajès V, Sattler W, Stranzl A, Kostner GM.
    Breast Cancer Res Treat; 1995 Jun 21; 34(3):199-212. PubMed ID: 7579484
    [Abstract] [Full Text] [Related]

  • 19. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M.
    Cancer Res; 2002 Sep 01; 62(17):4977-84. PubMed ID: 12208749
    [Abstract] [Full Text] [Related]

  • 20. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
    Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L.
    Clin Cancer Res; 2007 Apr 01; 13(7):2061-7. PubMed ID: 17404087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.